Selkirk Pharma vs BioNTech
Side-by-side comparison of AI visibility scores, market position, and capabilities
Contract Development & Manufacturing Organization (CDMO) — Sterile Injectables
Selkirk Pharma is a US-based CDMO specializing in aseptic fill/finish for sterile injectable drug products; raised $82M+ total; operates a 115,000 sq ft GMP facility in Spokane, WA; blueprinted a $90M expansion factory;
About
Selkirk Pharma is a contract development and manufacturing organization (CDMO) founded in 2018 by fill/finish industry veterans and headquartered in Spokane, Washington. The company was purpose-built to address the domestic shortage of aseptic fill/finish manufacturing capacity for sterile injectable drug products — a segment critical to biologics, small molecules, and parenteral medicines. Its 115,000-square-foot GMP facility at the Pacific Northwest Technology Park operates with advanced isolator technology from SKAN, Bausch and Strobel VarioSys dose-filling systems, and single-use systems designed to meet both US FDA and EU Annex 1 compliance standards.
German mRNA pioneer co-developed COVID-19 vaccine with Pfizer; 20+ clinical programs in oncology and infectious disease;
About
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneered individualized neoantigen-specific immunotherapy and mRNA-based therapeutic approaches before co-developing the world's first authorized mRNA vaccine with Pfizer during the COVID-19 pandemic.\n\nBioNTech's pipeline spans over 20 clinical programs in oncology, infectious disease, and autoimmune conditions. Key assets include BNT111, an mRNA cancer vaccine for melanoma evaluated in combination with Regeneron's cemiplimab, as well as a suite of CAR-T, bispecific antibody, and mRNA-encoded cytokine programs. The company manufactures mRNA therapies at scale through its BioNTainer modular facilities deployable to emerging markets.\n\nBioNTech generated approximately €2.4 billion in revenue in 2024 and holds a robust cash position exceeding €17 billion, enabling sustained R&D investment. The company is recognized as one of the most pivotal biotech success stories of the 21st century, combining deep immunology science with scalable mRNA manufacturing to pursue a world where cancer is a manageable disease.
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.